 SLAMF2 and SLAMF4 interact with one another, but all other SLAMF receptors are self-ligands, meaning that they interact with the corresponding receptor on other cells in a homophilic way.SLAMFs are potential targets for immunotherapy.For example, elotuzumab is an anti-SLAMF7 humanized monoclonal antibody used to treat multiple myeloma.